| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Matinas Biopharma Holdings Inc. | MAT2203 - (ORALTO) | Invasive aspergillosis | Phase 3 | Withdrawn | oral | Anti-Fungal |
| Matinas Biopharma Holdings Inc. | MAT9001 - (ENHANCE-IT) | Severe hypertriglyceridemia | Phase 2 | Trial Discontinued | Oral | Endocrinology |
| Maze Therapeutics Inc. | MZE829 | APOL1 kidney disease | Phase 2 | Trial Planned | Oral | Genetic Disorder |
| Maze Therapeutics Inc. | MZE782 | Phenylketonuria (PKU) | Phase 2 | Trial Planned | oral | Genetic Disorder |
| Maze Therapeutics Inc. | MZE782 | Chronic Kidney Disease (CKD) | Phase 2 | Trial Planned | oral | N/A |
| MBX Biosciences Inc. | Canvuparatide (MBX 2109) - (Avail) | Hypoparathyroidism | Phase 2 | Data Released | Subcutaneous | Endocrinology |
| Medicenna Therapeutics Corp. | MDNA55 (bizaxofusp) - (LIGHT) | Recurrent Glioblastoma (GBM) | Phase 2b | Data Released | Intratumoral | Oncology |
| MediciNova Inc. | Ibudilast (MN-166) - (COMBAT-ALS) | Amyotrophic lateral sclerosis (ALS) | Phase 2/3 | Enrollment Conclusion | Oral | Neurology |